 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company or the Group, today announces 12-month topline data from the Companys Phase 2b dose-ranging ASTEROID clinical study of setrusumab BPS-804, an anti-sclerostin antibody, in adults with Type I, III or IV osteogenesis imperfecta OI, a rare bone disease with no approved treatments. ASTEROID was the largest, prospectively-designed, interventional clinical study to be performed in this patient group. 